The Retreat

Lice Clinics of America Opens New Clinic in Middleborough, MA

Retrieved on: 
Wednesday, October 25, 2023

Families dealing with head lice in the area can now receive professional treatments at Lice Clinics of America, operated by Lice Aunties.

Key Points: 
  • Families dealing with head lice in the area can now receive professional treatments at Lice Clinics of America, operated by Lice Aunties.
  • The clinic provides screening, diagnosis and treatment for people dealing with head lice using an advanced medical technology called AirAllé®, an FDA-cleared, Class I medical device clinically proven to kill live lice and more than 99 percent of eggs, including lice that are resistant to traditional lice products.
  • “Many parents find that treating lice at home is a challenge,” says Dr. Krista Lauer, medical director of Lice Clinics of America.
  • “Our clinics provide comfort to kids dealing with head lice, so we thought this would be the perfect foundation to partner with.”
    Golden, who also owns and operates two additional Lice Clinics of America locations operated by Lice Aunties in Woburn and Newton, says the best part of her job is helping families.

Lice Clinics of America Opens New Clinic in San Jose

Retrieved on: 
Friday, September 29, 2023

San Jose, CA – September 25, 2023 – The country’s largest lice-removal clinic group has opened a new location in San Jose.

Key Points: 
  • San Jose, CA – September 25, 2023 – The country’s largest lice-removal clinic group has opened a new location in San Jose.
  • Families dealing with head lice in the area can now enjoy a professional treatment at Lice Clinics of America located at 1155 Redmond Avenue in San Jose.
  • “Many parents find that treating lice at home is a challenge,” says Dr. Krista Lauer, medical director of Lice Clinics of America.
  • The clinic is independently owned and operated by Lice Clinics of America franchisee William and Amy Allen, who got into the business after their oldest daughter encountered head lice and had her treated with the AirAllé at Lice Clinics of America.

U.S. FDA Approves First Therapeutic Indication for Revance’s DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Retrieved on: 
Monday, August 14, 2023

Peter McAllister, M.D., ASPEN investigator and co-founder and medical director of the New England Institute for Neurology and Headache, commented: “As an ASPEN investigator, I am excited to see the approval of a new treatment option to address symptom reemergence prior to retreatment, a common issue for cervical dystonia patients. Currently, patients experience painful and life-limiting symptom recurrence as early as eight to 10 weeks in clinical practice but cannot be re-treated until 12 weeks. DAXXIFY® is the first long-acting neuromodulator that has the potential to address this significant unmet need -- demonstrating durable symptom relief between treatment cycles and providing the opportunity to extend treatment intervals.”

Key Points: 
  • In 2017, the U.S. FDA granted orphan drug designation to DAXXIFY® for the treatment of cervical dystonia in adults.
  • Further, we believe FDA approval represents a significant advancement in the treatment of cervical dystonia,” said Chief Executive Officer Mark J. Foley.
  • “DAXXIFY’s differentiated efficacy, duration and safety profile can help physicians deliver long-lasting symptom relief to patients suffering from cervical dystonia, while also helping payers address the total cost of care for this population.
  • DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Retrieved on: 
Tuesday, June 27, 2023

NKX101 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target NKG2D ligands on cancer cells.

Key Points: 
  • NKX101 is an allogeneic, off-the-shelf cell therapy candidate comprising NK cells derived from healthy donors and engineered to target NKG2D ligands on cancer cells.
  • Ara-C is an established and important drug in the treatment of AML across treatment lines, including first line therapy.
  • “Patients with relapsed or refractory AML have few treatment options, and novel approaches are urgently needed.
  • NKX101 is being evaluated in a dose-escalation Phase 1 study as a multi-dose, multi-cycle cellular therapy in patients with r/r AML.

argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy

Retrieved on: 
Tuesday, June 20, 2023

“We are encouraged by the favorable safety profile and early efficacy signals from the ARDA study, as well as the IDMC recommendation to advance the study to the next cohort.

Key Points: 
  • “We are encouraged by the favorable safety profile and early efficacy signals from the ARDA study, as well as the IDMC recommendation to advance the study to the next cohort.
  • The IDMC confirmed a favorable safety and tolerability profile of empasiprubart consistent with results from the Phase 1 study and recommended advancing to the second cohort.
  • The study’s objective, in addition to assessing safety and efficacy of empasiprubart, is to populate a PK/PD model to inform the Phase 3 study dose selection.
  • The Phase 2 ARDA study is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of two dose regimens of empasiprubart in adults with multifocal motor neuropathy (MMN).

Nkarta Presents NKX019 Clinical Data at the European Hematology Association 2023 Congress and 17th International Conference on Malignant Lymphoma

Retrieved on: 
Saturday, June 10, 2023

SOUTH SAN FRANCISCO, Calif., June 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., June 10, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced presentations highlighting preliminary data based on a November 2022 data cut-off from its Phase 1 dose escalation clinical trial of NKX019 at two scientific conferences: the European Hematology Association (EHA) 2023 Hybrid Congress and the 17th International Conference on Malignant Lymphoma (17-ICML).
  • NKX019 is an allogeneic, off-the-shelf NK cell therapy candidate derived from healthy donors and engineered to target CD19.
  • The presentations will ensure that the broader clinical and academic community has the opportunity to assess the NKX019 clinical data in a peer-reviewed format.
  • Nkarta plans to provide an update from the NKX019 program, including data from dose expansion cohorts, in 2023.

Dr. Neil A. Gordon Honored as Keynote Speaker at International Plastic Surgery Conference in Brazil, 2023

Retrieved on: 
Thursday, June 8, 2023

WILTON, Conn., June 8, 2023 /PRNewswire-PRWeb/ -- Board-certified facial plastic surgeon Dr. Neil A. Gordon was honored to be invited and serve as a keynote speaker on March 10-11 at the 2023 International Plastic Surgery Symposium (SIMPO) in São Paulo, Brazil, at the Sheraton Hotel. SIMPO focuses on topics like anatomy and facial surgery, neck lift, surgical demonstrations, rhinoplasty, breast augmentation, and the discussion of intercurrences and complex cases.

Key Points: 
  • WILTON, Conn., June 8, 2023 /PRNewswire-PRWeb/ -- Board-certified facial plastic surgeon Dr. Neil A. Gordon was honored to be invited and serve as a keynote speaker on March 10-11 at the 2023 International Plastic Surgery Symposium (SIMPO) in São Paulo, Brazil, at the Sheraton Hotel.
  • Dr. Gordon was the keynote speaker and performed a live deep plane facelift,
    streamed to thousands of surgeons around the world, in Brazil at the SIMPO International Conference in 2023.
  • In 2021, Dr. Gordon was honored to be the sole speaker and presenter at the first "Deep Plane Brazil '' conference in Sao Paolo.
  • In March 2023, Dr. Gordon performed a live surgery at the SIMPO Conference before the Brazilian Plastic Surgery Society.

Acutus Medical to Showcase Innovative Cardiac Mapping and Ablation Technologies at HRS 2023

Retrieved on: 
Monday, May 15, 2023

As an exhibitor at HRS, Acutus Medical will showcase its latest groundbreaking electrophysiology systems and technologies, including AcQMap®, the industry's only whole-chamber, single-beat, non-contact mapping system.

Key Points: 
  • As an exhibitor at HRS, Acutus Medical will showcase its latest groundbreaking electrophysiology systems and technologies, including AcQMap®, the industry's only whole-chamber, single-beat, non-contact mapping system.
  • “We are pleased to join HRS ’23 to offer the industry an opportunity to engage directly with our state-of-the-art cardiac mapping and ablation therapy technologies, as well as meet with many of our key physician partners,” said David Roman, President & CEO of Acutus Medical.
  • In addition to Dr. Betts’ presentation, Acutus Medical is hosting a wide variety of events, including a range of peer-to-peer presentations from leading cardiac electrophysiologists and current Acutus users, live demonstrations and case reviews, and physician-led discussions.
  • “As a pioneer in the field of electrophysiology, Acutus Medical delivers cutting-edge tools that provide critical information conventional mapping systems cannot, which helps physicians deliver personalized therapy for atrial arrhythmias,” said Shibaji Shome, Ph.D., Vice President of Marketing at Acutus Medical.

Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights

Retrieved on: 
Thursday, May 11, 2023

Cash and Cash Equivalents: As of March 31, 2023, Nkarta had cash, cash equivalents, restricted cash, and investments of $332.1 million.

Key Points: 
  • Cash and Cash Equivalents: As of March 31, 2023, Nkarta had cash, cash equivalents, restricted cash, and investments of $332.1 million.
  • Non-cash stock-based compensation expense included in R&D expense was $2.1 million for the first quarter of 2023.
  • Non-cash stock-based compensation expense included in G&A expense was $2.7 million for the first quarter of 2023.
  • Net Loss: Net loss was $30.8 million, or $0.63 per basic and diluted share, for the first quarter of 2023.

Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results

Retrieved on: 
Thursday, April 20, 2023

CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to the release of the RECOVER AF study data (published online in EP Europace)1.

Key Points: 
  • CARLSBAD, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the first quarter 2023 in addition to the release of the RECOVER AF study data (published online in EP Europace)1.
  • The Company expects first quarter 2023 revenue in the range of $4.1-$4.2 million compared to $3.7 million in the first quarter of 2022.
  • As expected, the Company’s results for the first quarter of 2023 were adversely impacted by supply chain shortages that are expected to be resolved in the balance of the year.
  • While we had a slow start in terms of AcQMap cases, we saw a progressive increase in procedure volume by quarter end,” said David Roman, President & CEO of Acutus.